Pre-Market Most Active for Aug 7, 2025 : INTC, NVO, TSLL, SQQQ, QBTS, PTON, NVDA, TQQQ, LLY, IONQ, BBAI, JOBY
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Should l Buy NVO?
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Performance: The NASDAQ 100 is up 174.24 points, with a total pre-market volume of approximately 125.9 million shares traded. Active stocks include Intel Corporation, Novo Nordisk, and NVIDIA, among others, showing varied price movements.
Stock Highlights: Notable stock performances include Intel down slightly, Novo Nordisk reaching a 52-week high, and ProShares UltraPro QQQ showing significant gains from its low. Eli Lilly experienced a notable drop, while several companies have upcoming earnings reports or revisions in forecasts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 35.290
Low
42.00
Averages
54.67
High
70.00
Current: 35.290
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Launches Wegovy Subscription Program for Weight Loss Therapy
- Innovative Subscription Model: Novo Nordisk has launched the first-ever Wegovy (semaglutide) subscription program, allowing patients to choose 3-, 6-, or 12-month subscriptions through telehealth platforms like LifeMD and Hims & Hers, aimed at reducing treatment barriers and enhancing drug accessibility.
- Cost Savings Advantage: According to the company, patients on a 12-month subscription can save up to $600 annually on Wegovy pills and $1,200 on Wegovy injections, significantly alleviating financial burdens and promoting long-term treatment adherence.
- Market Expansion Strategy: Initially available through platforms like Ro, WeightWatchers, and LifeMD, the program is set to expand to Hims & Hers and Sesame, reflecting Novo Nordisk's strategic positioning and intent to penetrate the digital health market.
- Patient Support Commitment: Ed Cinca, Senior Vice President at Novo, stated that the subscription program offers patients a simple, affordable, and consistent FDA-approved treatment option, aimed at enhancing patient experience and satisfaction, thereby solidifying the company's leadership in the weight loss medication market.
See More
Omeros Reports Significant Q4 Turnaround with $86.5M Net Income
- Successful Asset Transaction: Omeros closed a significant asset purchase and licensing deal with Novo Nordisk valued at up to $2.1 billion, providing a $240 million upfront payment that will bolster the company's future R&D and market expansion efforts.
- FDA Approval Milestone: The FDA's approval of YARTEMLEA as the first and only treatment for TA-TMA marks a significant breakthrough for the company in the biopharmaceutical sector, expected to drive sales growth moving forward.
- Improved Financial Performance: Omeros reported a net income of $86.5 million for Q4 2025, a substantial turnaround from a net loss of $30.9 million in the previous quarter, indicating a strong recovery in business operations and enhanced profitability.
- Debt Management Optimization: The company successfully repaid a significant portion of its debt, leaving only $70.8 million in outstanding convertible notes, which significantly improves its balance sheet and lays a foundation for future financial sustainability.
See More
Omeros Reports Strong Q4 Results with Novo Nordisk Deal
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
See More
Rhythm Pharmaceuticals Gains FDA Approval for Expanded Market
- Market Expansion Opportunity: Rhythm Pharmaceuticals' Imcivree, approved in 2020 for chronic obesity treatment due to specific protein deficiencies, achieved $189.8 million in sales for 2025, reflecting a nearly 46% year-over-year growth, indicating strong market demand and growth potential.
- FDA New Approval: On March 19, 2023, Rhythm Pharmaceuticals announced that the FDA granted approval for Imcivree for patients with acquired hypothalamic obesity, potentially adding 10,000 patients and expanding the target market from 7,500 to 17,500, significantly enhancing market coverage.
- Clinical Trial Risks: Despite the new indication, Imcivree failed to meet its primary endpoint in a phase 3 trial for obesity treatment in patients with certain genetic conditions, increasing uncertainty around future approvals and potentially impacting the company's market outlook.
- Profitability Challenges: Rhythm Pharmaceuticals faces ongoing profitability risks and intense competition in a small market; while there are other pipeline candidates, the overall profit outlook remains unclear, necessitating cautious risk assessment by investors.
See More
Market Rallies on Signs of Iran Conflict De-escalation
- Market Rally: The S&P 500 surged over 2% on Tuesday amid signs of potential de-escalation in the Iran conflict, reflecting investor optimism, although caution is still warranted regarding this signal.
- Eli Lilly Acquisition: Eli Lilly announced its acquisition of Centessa Pharmaceuticals for up to $7.8 billion, focusing on new treatments for excessive daytime sleepiness, with peak sales for its key asset cleminorexton projected to exceed $3 billion, further solidifying Lilly's position in neuroscience.
- Novo Nordisk Competition: Novo Nordisk launched a subscription program to lower prices on Wegovy, aiming to reclaim market share from Eli Lilly, which leads in the GLP-1 category, highlighting the need for continuous innovation to maintain competitive advantage.
- Analyst Ratings: Truist initiated coverage of Corning with a hold rating and a $125 price target, expressing optimism about its optical business growth while raising concerns over current valuations, indicating a cautious market outlook on Corning's future growth potential.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Novo Nordisk Launches Wegovy Subscription Program for Weight Loss Therapy
- Innovative Subscription Model: Novo Nordisk has launched the first-ever Wegovy (semaglutide) subscription program, allowing patients to choose 3-, 6-, or 12-month subscriptions through telehealth platforms like LifeMD and Hims & Hers, aimed at reducing treatment barriers and enhancing drug accessibility.
- Cost Savings Advantage: According to the company, patients on a 12-month subscription can save up to $600 annually on Wegovy pills and $1,200 on Wegovy injections, significantly alleviating financial burdens and promoting long-term treatment adherence.
- Market Expansion Strategy: Initially available through platforms like Ro, WeightWatchers, and LifeMD, the program is set to expand to Hims & Hers and Sesame, reflecting Novo Nordisk's strategic positioning and intent to penetrate the digital health market.
- Patient Support Commitment: Ed Cinca, Senior Vice President at Novo, stated that the subscription program offers patients a simple, affordable, and consistent FDA-approved treatment option, aimed at enhancing patient experience and satisfaction, thereby solidifying the company's leadership in the weight loss medication market.
See More
Omeros Reports Significant Q4 Turnaround with $86.5M Net Income
- Successful Asset Transaction: Omeros closed a significant asset purchase and licensing deal with Novo Nordisk valued at up to $2.1 billion, providing a $240 million upfront payment that will bolster the company's future R&D and market expansion efforts.
- FDA Approval Milestone: The FDA's approval of YARTEMLEA as the first and only treatment for TA-TMA marks a significant breakthrough for the company in the biopharmaceutical sector, expected to drive sales growth moving forward.
- Improved Financial Performance: Omeros reported a net income of $86.5 million for Q4 2025, a substantial turnaround from a net loss of $30.9 million in the previous quarter, indicating a strong recovery in business operations and enhanced profitability.
- Debt Management Optimization: The company successfully repaid a significant portion of its debt, leaving only $70.8 million in outstanding convertible notes, which significantly improves its balance sheet and lays a foundation for future financial sustainability.
See More
Omeros Reports Strong Q4 Results with Novo Nordisk Deal
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
See More
Rhythm Pharmaceuticals Gains FDA Approval for Expanded Market
- Market Expansion Opportunity: Rhythm Pharmaceuticals' Imcivree, approved in 2020 for chronic obesity treatment due to specific protein deficiencies, achieved $189.8 million in sales for 2025, reflecting a nearly 46% year-over-year growth, indicating strong market demand and growth potential.
- FDA New Approval: On March 19, 2023, Rhythm Pharmaceuticals announced that the FDA granted approval for Imcivree for patients with acquired hypothalamic obesity, potentially adding 10,000 patients and expanding the target market from 7,500 to 17,500, significantly enhancing market coverage.
- Clinical Trial Risks: Despite the new indication, Imcivree failed to meet its primary endpoint in a phase 3 trial for obesity treatment in patients with certain genetic conditions, increasing uncertainty around future approvals and potentially impacting the company's market outlook.
- Profitability Challenges: Rhythm Pharmaceuticals faces ongoing profitability risks and intense competition in a small market; while there are other pipeline candidates, the overall profit outlook remains unclear, necessitating cautious risk assessment by investors.
See More
Market Rallies on Signs of Iran Conflict De-escalation
- Market Rally: The S&P 500 surged over 2% on Tuesday amid signs of potential de-escalation in the Iran conflict, reflecting investor optimism, although caution is still warranted regarding this signal.
- Eli Lilly Acquisition: Eli Lilly announced its acquisition of Centessa Pharmaceuticals for up to $7.8 billion, focusing on new treatments for excessive daytime sleepiness, with peak sales for its key asset cleminorexton projected to exceed $3 billion, further solidifying Lilly's position in neuroscience.
- Novo Nordisk Competition: Novo Nordisk launched a subscription program to lower prices on Wegovy, aiming to reclaim market share from Eli Lilly, which leads in the GLP-1 category, highlighting the need for continuous innovation to maintain competitive advantage.
- Analyst Ratings: Truist initiated coverage of Corning with a hold rating and a $125 price target, expressing optimism about its optical business growth while raising concerns over current valuations, indicating a cautious market outlook on Corning's future growth potential.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
